Research over 5,000 times in October, private equity firms target the technology and pharmaceutical sectors.

Entering the fourth quarter, institutional research remains active. Data from the Privately Treated Network show that in October, private equity research saw significant growth in terms of participating institution size, coverage of listed companies, and frequency of research compared to September. In terms of research direction, the electronics and pharmaceutical sectors are still favored. In the view of industry insiders, with reasonable market liquidity and rapid development of China's advantageous industries, structural opportunities in A-shares and Hong Kong shares will continue to emerge, and targets with broad growth potential and performance certainty are worth paying attention to.